Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
Provided By GlobeNewswire
Last update: Oct 29, 2024
REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights.
Read more at globenewswire.com
